Pharmaids Pharmaceuticals Ltd
₹ 73.9
-3.66%
21 Nov
- close price
About
Incorporated in 1989, Pharmaids Pharmaceuticals Ltd manufactures Bulk Drugs and Intermediaries.
Key Points
- Market Cap ₹ 261 Cr.
- Current Price ₹ 73.9
- High / Low ₹ 87.5 / 31.9
- Stock P/E
- Book Value ₹ 19.4
- Dividend Yield 0.00 %
- ROCE -10.8 %
- ROE -10.6 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.81 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -0.37%
- The company has delivered a poor sales growth of -44.3% over past five years.
- Promoter holding is low: 5.19%
- Company has a low return on equity of -17.4% over last 3 years.
- Working capital days have increased from 8,204 days to 16,425 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.27 | 1.39 | 1.73 | 1.68 | 1.20 | 0.45 | 0.56 | 0.00 | 8.55 | 3.94 | 0.00 | 0.03 | 1.03 | |
| 1.20 | 1.83 | 1.82 | 2.03 | 1.54 | 0.84 | 0.67 | 0.34 | 8.45 | 3.81 | 9.89 | 6.41 | 6.99 | |
| Operating Profit | 0.07 | -0.44 | -0.09 | -0.35 | -0.34 | -0.39 | -0.11 | -0.34 | 0.10 | 0.13 | -9.89 | -6.38 | -5.96 |
| OPM % | 5.51% | -31.65% | -5.20% | -20.83% | -28.33% | -86.67% | -19.64% | 1.17% | 3.30% | -21,266.67% | -578.64% | ||
| 0.05 | 0.16 | 0.12 | 0.05 | 0.53 | 0.02 | 0.01 | 0.00 | 0.03 | 0.02 | 0.00 | 0.80 | -0.86 | |
| Interest | 0.01 | 0.01 | 0.00 | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.33 | 0.31 |
| Depreciation | 0.07 | 0.08 | 0.14 | 0.10 | 0.06 | 0.00 | 0.05 | 0.04 | 0.04 | 0.01 | 0.02 | 0.18 | 0.16 |
| Profit before tax | 0.04 | -0.37 | -0.11 | -0.43 | 0.09 | -0.37 | -0.15 | -0.38 | 0.09 | 0.14 | -9.91 | -6.09 | -7.29 |
| Tax % | -25.00% | -2.70% | -36.36% | -6.98% | -33.33% | 5.41% | 20.00% | -107.89% | 0.00% | 0.00% | -23.71% | -18.72% | |
| 0.05 | -0.35 | -0.07 | -0.40 | 0.11 | -0.39 | -0.18 | 0.03 | 0.09 | 0.15 | -7.56 | -4.95 | -6.50 | |
| EPS in Rs | 0.15 | -1.03 | -0.21 | -1.17 | 0.32 | -1.15 | -0.53 | 0.03 | 0.09 | 0.15 | -3.52 | -1.40 | -2.15 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -32% |
| 5 Years: | -44% |
| 3 Years: | -85% |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 39% |
| 5 Years: | 72% |
| 3 Years: | 66% |
| 1 Year: | 81% |
| Return on Equity | |
|---|---|
| 10 Years: | -14% |
| 5 Years: | -14% |
| 3 Years: | -17% |
| Last Year: | -11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.36 | 3.36 | 3.36 | 3.36 | 3.36 | 3.36 | 10.27 | 10.27 | 10.27 | 10.27 | 21.44 | 35.27 | 35.27 |
| Reserves | -1.19 | -1.55 | -1.65 | -2.05 | -1.94 | -2.32 | -1.87 | -1.84 | -1.74 | -1.60 | 0.98 | 35.79 | 33.16 |
| 0.44 | 0.36 | 0.30 | 0.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.93 | 14.52 | |
| 0.57 | 0.72 | 0.51 | 0.51 | 0.60 | 0.26 | 0.27 | 0.03 | 0.59 | 2.44 | 2.14 | 1.00 | 1.50 | |
| Total Liabilities | 3.18 | 2.89 | 2.52 | 2.30 | 2.02 | 1.30 | 8.67 | 8.46 | 9.12 | 11.11 | 24.56 | 84.99 | 84.45 |
| 0.69 | 0.62 | 0.46 | 0.44 | 0.00 | 0.00 | 0.08 | 0.08 | 0.04 | 0.03 | 0.11 | 16.55 | 16.53 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 | 0.45 | 0.45 | 0.45 | 2.00 | 2.30 | 2.31 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.27 | 52.60 | 52.60 |
| 2.49 | 2.27 | 2.06 | 1.86 | 2.02 | 1.30 | 8.14 | 7.93 | 8.63 | 10.63 | 19.18 | 13.54 | 13.01 | |
| Total Assets | 3.18 | 2.89 | 2.52 | 2.30 | 2.02 | 1.30 | 8.67 | 8.46 | 9.12 | 11.11 | 24.56 | 84.99 | 84.45 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.17 | 0.08 | 0.21 | 0.02 | 0.33 | -0.21 | -0.10 | -0.75 | 0.41 | -0.26 | -4.02 | -3.44 | |
| 0.00 | 0.00 | -0.01 | -0.08 | 0.33 | -0.09 | 0.00 | 0.66 | -0.23 | 0.47 | -4.95 | -72.51 | |
| -0.04 | -0.10 | -0.13 | 0.05 | -0.22 | -0.07 | -0.03 | 0.00 | 0.00 | 0.00 | 21.31 | 65.66 | |
| Net Cash Flow | 0.13 | -0.02 | 0.06 | -0.01 | 0.43 | -0.37 | -0.13 | -0.09 | 0.18 | 0.21 | 12.35 | -10.29 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 454.09 | 330.86 | 234.19 | 232.47 | 240.29 | 421.78 | 580.09 | 11.95 | 124.14 | 0.00 | ||
| Inventory Days | 94.47 | 104.29 | 102.77 | 91.25 | 130.75 | 0.00 | 0.00 | 16.55 | 90.99 | 0.00 | 4,197.50 | |
| Days Payable | 163.18 | 197.40 | 145.29 | 138.45 | 245.15 | 22.37 | 236.18 | 0.00 | ||||
| Cash Conversion Cycle | 385.39 | 237.75 | 191.67 | 185.27 | 125.89 | 421.78 | 580.09 | 6.14 | -21.05 | 4,197.50 | ||
| Working Capital Days | 393.74 | 249.46 | 200.43 | 193.36 | 161.21 | 227.11 | 2,652.77 | 2.99 | -17.60 | 16,425.00 | ||
| ROCE % | 1.90% | -15.06% | -5.26% | -21.05% | -24.30% | -30.08% | -3.18% | -4.52% | 1.06% | 1.63% | -63.75% | -10.83% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Listing Regulations, 2015, enclosed herewith the copies of newspaper publications providing extracts of unaudited financial results for the quarter and half year ended on September …
-
Announcement Under Regulation 30 - Contact Details Of KMP For Determining Materiality Of Event/ Information And Making Disclosure.
13 Nov - Change in contact details of KMP.
-
Financial Results For The Quarter And Half Year Ended September 30, 2024
13 Nov - Approval of unaudited financial results for Q2 2024.
-
Board Meeting Outcome for Board Meeting Outcome For Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2024.
13 Nov - Approval of unaudited financial results for Q2 2024.
-
Announcement Under Regulation 30 (LODR) - Intimation On Loan Agreement.
9 Nov - Company enters loan agreement for Rs 12.5 Crore.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
a) Specialty Chemicals:[1] Retinol, DL Alpha Tocopherol, D-Pantothenate, Cyanocobalamin, Pyridoxine Hcl, Thiamine, Nicotinic Acid, Water Sol. Vitamin E, Coenzyme Q10, D-Biotin
b) Skin Care:[2] Best care hands, Hands Sanitizer, Moisturizing Cream, Skin-Sure Plus, Skin-Sure Ultra, Alcohol Gel, Barrier Cream
c) Hospital Care:[3] Xepi Rub M, Facein Spray, Sod Hypochlorite, Sanmedin, Strumen-G, Strumen TRIACID, Facein Eco, Facein Power, Facein Spray, Sod Hypochlorite, Wipes, PPE
d) Generics:[4] Linzomust, Ceforoot 1.5g, Trendyclav-L, Cobasure Gold 2ML INJ, Benfoshine, Amplimmune, Thiaxa T8, Molprime SR, Citibrain-Plus, Duojoint